Abstract
Aim: The emergence of antitumor immunotherapy has been beneficial for patients with tumors, but more attention should be paid to the toxic side effects of chemoimmunotherapy. Here we describe a patient with NK/T-cell lymphoma who developed toxic epidermal necrolysis (TEN) during treatment with a regimen consisting of sintilimab combined with pegaspargase, gemcitabine and oxaliplatin (P-GemOx). Case presentation: A patient received six cycles of P-GemOx chemotherapy as first-line treatment; 1 year later, he received the same dose of P-GemOx combined with sintilimab as chemoimmunotherapy due to recurrence of NK/T-cell lymphoma. He developed a massive rash that quickly developed into TEN after the fourth chemoimmunotherapy. Conclusion: Although rare, cases of fatal TEN caused by single-agent PD-1 inhibitor or gemcitabine have been reported. Careful attention to drug-related cutaneous toxicities is needed when these two agents are combined. This report highlights the significance of TEN as a rapid and serious adverse event induced by chemoimmunotherapy.
Plain language summary
Immune checkpoint inhibitors that block the interaction of PD-1 with its ligand, PD-L1, have been increasingly used in cancer therapy. However, some rare side effects induced by these drugs, such as toxic epidermal necrolysis (TEN), can be extremely dangerous. Here we describe a patient with natural killer/T-cell lymphoma who developed TEN during treatment with a combination of sintilimab and pegaspargase/gemcitabine/oxaliplatin (P-GemOx). The patient received six cycles of P-GemOx chemotherapy as first-line treatment and showed no skin reactions during or after treatment. However, 1 year later, the patient received the same dose of P-GemOx combined with sintilimab as second-line treatment for recurrent natural killer/T-cell lymphoma and developed a massive rash that quickly developed into TEN after four cycles of chemoimmunotherapy. Cutaneous toxicities are some of the most prevalent immune-related adverse events, both with anti-PD-1 and anti-PD-L1 agents, which correspond to a class effect.
Papers of special note have been highlighted as: • of interest; •• of considerable interest
References
- 1. . Stevens–Johnson syndrome and toxic epidermal necrolysis: a concise review with a comprehensive summary of therapeutic interventions emphasizing supportive measures. Adv. Ther. 34(6), 1235–1244 (2017). • Summary of appropriate management of TEN, including supportive care and adjuvant therapies.
- 2. Extranodal natural killer T-cell lymphoma, nasal-type: a prognostic model from a retrospective multicenter study. J. Clin. Oncol. 24(4), 612–618 (2006).
- 3. . Sintilimab: first global approval. Drugs 79(3), 341–346 (2019).
- 4. . SCORTEN: a severity-of-illness score for toxic epidermal necrolysis. J. Invest. Dermatol. 115(2), 149–153 (2000). • Provides a scale that can be used to predict mortality in patients with TEN.
- 5. . A clinicotherapeutic analysis of Stevens–Johnson syndrome and toxic epidermal necrolysis with an emphasis on the predictive value and accuracy of SCORe of Toxic Epidermal Necrolysis. Int. J. Dermatol. 54(1), e18–e26 (2015).
- 6. . Stevens Johnson syndrome and toxic epidermal necrolysis – an Australian analysis of treatment outcomes and mortality. J. Dermatolog. Treat. 30(7), 718–723 (2019).
- 7. . Stevens–Johnson syndrome and toxic epidermal necrolysis: a retrospective descriptive study. Int. J. Dermatol. 58(11), 1293–1299 (2019).
- 8. . What we should know about natural killer/T-cell lymphomas. Hematol. Oncol. 37(Suppl. 1), 75–81 (2019).
- 9. . The diagnosis and management of NK/T-cell lymphomas. J. Hematol. Oncol. 10(1), 85 (2017).
- 10. . Advances in the treatment of extranodal NK/T-cell lymphoma, nasal type. Blood 131(23), 2528–2540 (2018).
- 11. . Immune-related adverse events (irAEs): diagnosis, management, and clinical pearls. Curr. Oncol. Rep. 22(4), 39 (2020). • Provides the diagnostic criteria and management for irAEs.
- 12. . Stevens–Johnson syndrome and toxic epidermal necrolysis: an analysis of triggers and implications for improving prevention. Am. J. Med. 129(11), 1221–1225 (2016).
- 13. . Markers of systemic involvement and death in hospitalized cancer patients with severe cutaneous adverse reactions. J. Am. Acad. Dermatol. 80(3), 608–616 (2019).
- 14. . Current perspectives on Stevens–Johnson syndrome and toxic epidermal necrolysis. Clin. Rev. Allergy Immunol. 54(1), 147–176 (2018). • Provides the diagnostic criteria for TEN.
- 15. Epidermal programmed cell death-ligand 1 expression in TEN associated with nivolumab therapy. J. Cutan. Pathol. 44(4), 381–384 (2017).
- 16. . Toxic epidermal necrolysis (TEN) associated with the use of nivolumab (PD-1 inhibitor) for lymphoma. JAAD Case Rep. 4(3), 229–231 (2018).
- 17. Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study. Lancet 393(10167), 156–167 (2019).
- 18. . Immune-mediated toxic epidermal necrolysis. Cureus 12(8), e9587 (2020).
- 19. Treatment-related adverse events of PD-1 and PD-L1 inhibitors in clinical trials: a systematic review and meta-analysis. JAMA Oncol. 5(7), 1008–1019 (2019).
- 20. . Stevens–Johnson syndrome/toxic epidermal necrolysis in a patient receiving concurrent radiation and gemcitabine. Anticancer Drugs 14(8), 659–662 (2003).
- 21. . Toxic epidermal necrolysis associated with gemcitabine therapy in a patient with metastatic transitional cell carcinoma of the bladder. J. Chemother. 15(5), 510–511 (2003).
- 22. . Stevens–Johnson syndrome patient received combination chemotherapy gemcitabine, cisplatin, and 5-FU for biliary tract cancer. Iran. J. Cancer Prev. 9(3), e4211 (2016).
- 23. Widespread skin necrosis secondary to gemcitabine therapy. J. Drugs Dermatol. 17(5), 582–585 (2018).
- 24. Safety and activity of sintilimab in patients with relapsed or refractory classical Hodgkin lymphoma (ORIENT-1): a multicentre, single-arm, phase 2 trial. Lancet Haematol. 6(1), e12–e19 (2019). •• Summary of basic knowledge of sintilimab, especially the pharmacokinetics.
- 25. ALDEN, an algorithm for assessment of drug causality in Stevens–Johnson syndrome and toxic epidermal necrolysis: comparison with case-control analysis. Clin. Pharmacol. Ther. 88(1), 60–68 (2010). •• Provides a scale that can be used to find out which drug is most likely to have caused TEN.
- 26. . A case report of toxic epidermal necrolysis (TEN) in a patient with COVID-19 treated with hydroxychloroquine: are these two partners in crime? Clin. Mol. Allergy 18, 19 (2020).
- 27. . Enhancing antitumor response by combining immune checkpoint inhibitors with chemotherapy in solid tumors. Ann. Oncol. 30(2), 219–235 (2019).
- 28. First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer. N. Engl. J. Med. 379(23), 2220–2229 (2018).
- 29. Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial. Lancet 394(10212), 1929–1939 (2019).
- 30. Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial. Lancet 392(10142), 123–133 (2018).
- 31. . Checkpoint inhibitors for gastroesophageal cancers: dissecting heterogeneity to better understand their role in first-line and adjuvant therapy. Ann. Oncol. 32(5), 590–599 (2021).
- 32. . Perils with pirfenidone and ‘the tuberculosis link’. Int. J. Mycobacteriol. 8(3), 298–301 (2019).
- 33. . Exfoliative dermatitis to all four first line oral anti-tubercular drugs. Indian J. Tuberc. 57(1), 53–56 (2010).
- 34. . Immunogenic cell death in anticancer chemotherapy and its impact on clinical studies. Cancer Lett. 438, 17–23 (2018).
- 35. . Immunogenic cell death in cancer therapy: present and emerging inducers. J. Cell. Mol. Med. 23(8), 4854–4865 (2019).
- 36. . The efficacy and safety of immune checkpoint inhibitors in patients with cancer and preexisting autoimmune disease. Front. Oncol. 11, 625872 (2021). •• Review of safety profiles and adverse event profile of checkpoint inhibitors.
- 37. Immunotoxicity from checkpoint inhibitor therapy: clinical features and underlying mechanisms. Immunology 159(2), 167–177 (2020).
- 38. . Cutaneous adverse events of immune checkpoint inhibitors: a summarized overview. Curr. Drug Saf. 14(1), 14–20 (2019). •• Systematic review of TEN associated with immunotherapies.
- 39. . Dermatologic reactions to immune checkpoint inhibitors: skin toxicities and immunotherapy. Am. J. Clin. Dermatol 19(3), 345–361 (2018).
- 40. Immune checkpoint inhibitor-related dermatologic adverse events. J. Am. Acad. Dermatol. 83(5), 1255–1268 (2020).
- 41. . Glucocorticoid-induced apoptosis in lymphocytes. Biochem. Biophys. Res. Commun. 279(2), 307–312 (2000).
- 42. Immune-related adverse events of checkpoint inhibitors. Nat. Rev. Dis. Primers 6(1), 38 (2020).
- 43. . Efficacy and safety of cyclosporine in Stevens–Johnson syndrome and toxic epidermal necrolysis. Dermatol. Ther. 32(1), e12758 (2019).
- 44. NCCN Guidelines Insights: management of immunotherapy-related toxicities, version 1.2020. J. Natl Compr. Canc. Netw. 18(3), 230–241 (2020).
- 45. . Stevens–Johnson syndrome and toxic epidermal necrolysis: an update. Am. J. Clin. Dermatol. 16(6), 475–493 (2015).
- 46. New toxicity profile for novel immunotherapy agents: focus on immune-checkpoint inhibitors. Expert Opin. Drug Metab. Toxicol. 12(1), 57–75 (2016).